Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Total Current Liabilities (2023 - 2025)

Tonix Pharmaceuticals Holding has reported Total Current Liabilities over the past 3 years, most recently at $30.8 million for Q4 2025.

  • Quarterly results put Total Current Liabilities at $30.8 million for Q4 2025, up 68.44% from a year ago — trailing twelve months through Dec 2025 was $30.8 million (up 68.44% YoY), and the annual figure for FY2025 was $30.8 million, up 68.44%.
  • Total Current Liabilities for Q4 2025 was $30.8 million at Tonix Pharmaceuticals Holding, up from $21.0 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for TNXP hit a ceiling of $30.8 million in Q4 2025 and a floor of $12.1 million in Q1 2025.
  • Median Total Current Liabilities over the past 3 years was $18.7 million (2023), compared with a mean of $18.9 million.
  • Peak annual rise in Total Current Liabilities hit 68.44% in 2025, while the deepest fall reached 40.69% in 2025.
  • Tonix Pharmaceuticals Holding's Total Current Liabilities stood at $18.9 million in 2023, then dropped by 3.06% to $18.3 million in 2024, then skyrocketed by 68.44% to $30.8 million in 2025.
  • The last three reported values for Total Current Liabilities were $30.8 million (Q4 2025), $21.0 million (Q3 2025), and $19.1 million (Q2 2025) per Business Quant data.